Beijing Konruns Pharmaceutical (603590.SH): The KC1101 project has received a clinical trial notice.
Beijing Konruns Pharmaceutical (603590.SH) announced that recently, the company received a clinical trial notice approved and issued by the National Medical Products Administration for KC1101 tablets, a Class 1 innovative chemical drug. KC1101 is a TACC3-selective small molecule inhibitor independently developed by the company, intended for the treatment of advanced recurrent or metastatic solid tumors.
Beijing Konruns Pharmaceutical (603590.SH) announced that the company recently received a clinical trial notice approved and issued by the National Medical Products Administration for KC1101 tablets, a Class 1 innovative chemical drug. KC1101 is a TACC3-selective small molecule inhibitor independently developed by the company, intended for the treatment of advanced recurrent or metastatic solid tumors.
Related Articles

Tianjin Tianyao Pharmaceuticals (600488.SH): Marketing application for dexamethasone API approved

Jiangsu Lianhuan Pharmaceutical (600513.SH): Bilastine API Approved for Marketing

Palo Alto Networks (PANW.US) Q1 Earnings Call: Net addition of approximately 170 platformization deployments in the quarter! AI vulnerability discoveries approach 7 times last year's monthly average, enterprises begin tapping emergency budgets
Tianjin Tianyao Pharmaceuticals (600488.SH): Marketing application for dexamethasone API approved

Jiangsu Lianhuan Pharmaceutical (600513.SH): Bilastine API Approved for Marketing

Palo Alto Networks (PANW.US) Q1 Earnings Call: Net addition of approximately 170 platformization deployments in the quarter! AI vulnerability discoveries approach 7 times last year's monthly average, enterprises begin tapping emergency budgets






